CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Alembic Pharma Panelav facility receives 4 observations
Geyatee Deshpande
/ Categories: Trending, DSIJ News

Alembic Pharma Panelav facility receives 4 observations

Alembic Pharmaceuticals announced that US Food and Drug Administration (USFDA) conducted an inspection at Alembic Pharmaceuticals General Oral Solid Formulation Facility located in Panelav (Gujarat).

The inspection conducted by the regulator took place from March 9 to 13, 2020. At the conclusion of the inspection, USFDA issued a form 483 with four procedural observations. The company assured that none of the observations are related to data integrity or are repetitive in nature. Additionally, it also stated to immediately take comprehensive and corrective action for addressing the observations, so as to maintain high quality standards needed to meet USFDA standards.

Alembic Pharmaceuticals Ltd is a multinational pharmaceutical company headquartered in Vadodara (Gujarat). It is involved in the manufacture of pharmaceutical products, pharmaceutical substances and intermediates.

On Monday, the stock of the company closed at Rs 545.40, down by 5.15 per cent or Rs 29.60 per share. The 52-week high is Rs 682.50 and 52-week low is Rs 435.10 on BSE.

Previous Article Maruti expands its commercial network portfolio with tour range
Next Article Nilkamal Ltd board approves a big dividend
Print
1916 Rate this article:
4.0
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR